Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2810761 | 0.81 | ADORA2A (0.40) | DYRK1ANOS1KDM5AADORA2AADORA1 | |
| SCHEMBL20759134 | 0.78 | DYRK1A (0.33) | DYRK1AKDM5A | |
| SCHEMBL17065274 | 0.74 | KDM5A (0.37) | DYRK1AKDM5AADORA2AADORA1 | |
| SCHEMBL10026473 | 0.74 | MME (0.39) | DYRK1AKDM5A | |
| SCHEMBL25332845 | 0.73 | MEN1 (0.41) | DYRK1AKDM5AADORA2AADORA1 | |
| SCHEMBL19539129 | 0.70 | BRD4 (0.42) | KDM5A | |
| SCHEMBL1431340 | 0.70 | KMT2A (0.44) | KDM5A | |
| SCHEMBL12777937 | 0.70 | DYRK1A (0.40) | DYRK1AKDM5AADORA2AADORA1 | |
| SCHEMBL21756285 | 0.69 | GSK3B (0.35) | DYRK1AKDM5A | |
| SCHEMBL19531884 | 0.69 | KDM5A (0.41) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | VANDERBILT UNIVERSITY | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227470-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | DYRK1A 805/4885NOS1 2052/4885KDM5A 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.